Role of ethnic and genetic factors in the development of prostate cancer (Review)
- Authors:
- Timur Saliev
- Nurgulim Akhmad
- Saule Altynbekova
- Maral Nogaeva
- Aigul Tazhieva
- Zaure Dushimova
-
Affiliations: Institute for Fundamental and Applied Medical Research, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan, Department of Normal Anatomy, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan, Department of Endocrinology, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan, Department of Rheumatology, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan, Department of Science, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan, Department of Fundamental Medicine, Al‑Farabi Kazakh National University, Almaty 050040, Kazakhstan - Published online on: December 3, 2024 https://doi.org/10.3892/wasj.2024.301
- Article Number: 13
-
Copyright : © Saliev et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
 |
 |
 |
|
Harborg S, Kjærgaard KA, Thomsen RW, Borgquist S, Cronin-Fenton D and Hjorth CF: New horizons: Epidemiology of obesity, diabetes mellitus, and cancer prognosis. J Clin Endocrinol Metab. 109:924–935. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Varaprasad GL, Gupta VK, Prasad K, Kim E, Tej MB, Mohanty P, Verma HK, Raju GSR, Bhaskar L and Huh Y: Recent advances and future perspectives in the therapeutics of prostate cancer. Exp Hematol Oncol. 12(80)2023.PubMed/NCBI View Article : Google Scholar | |
|
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L, et al: 2022 update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 84:191–206. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Mumuni S, O'Donnell C and Doody O: The risk factors and screening uptake for prostate cancer: A scoping review. Healthcare (Basel). 11(2780)2023.PubMed/NCBI View Article : Google Scholar | |
|
Berenguer CV, Pereira F, Câmara JS and Pereira JAM: Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis. Curr Oncol. 30:2300–2321. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Babatunde OA, Pearce JL, Jefferson MS, Frey LJ, Angel PM, Drake RR, Allen CG, Lilly MB, Savage SJ and Halbert CH: Racial distribution of neighborhood-level social deprivation in a retrospective cohort of prostate cancer survivors. Diseases. 10(75)2022.PubMed/NCBI View Article : Google Scholar | |
|
Abashidze N, Stecher C, Rosenkrantz AB, Duszak R Jr and Hughes D: Racial and ethnic disparities in the use of prostate magnetic resonance imaging following an elevated prostate-specific antigen test. JAMA Netw Open. 4(e2132388)2021.PubMed/NCBI View Article : Google Scholar | |
|
Aristizabal C, Suther S, Yao Y, Behar-Horenstein LS, Webb F, Stern MC and Baezconde-Garbanati L: Training community African American and Hispanic/Latino/a advocates on prostate cancer (PCa): A multicultural and bicoastal approach. J Cancer Educ. 38:1719–1727. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Yang J, Xiong X, Zheng W, Liao X, Xu H, Yang L and Wei Q: Evaluation of survival outcomes among black and white patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Eur Urol Open Sci. 61:10–17. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Lee KY, Beatson EL, Steinberg SM, Chau CH, Price DK and Figg WD: Bridging health disparities: A genomics and transcriptomics analysis by race in prostate cancer. J Racial Ethn Health Disparities. 11:492–504. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Gu J, Chery L, González GMN, Huff C, Strom S, Jones JA, Griffith DP, Canfield SE, Wang X, Huang X, et al: A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening. Prostate. 84:694–705. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, et al: Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet. 55:2065–2074. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Owens OL, Dressler EV, Mayfield A, Winkfield KM, Krane LS, Foust M and Sandberg JC: Considerations from employed African-American and white prostate cancer survivors on prostate cancer treatment and survivorship: A qualitative analysis. Ethn Health. 29:309–327. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Wu D, Yang Y, Jiang M and Yao R: Competing risk of the specific mortality among Asian-American patients with prostate cancer: A surveillance, epidemiology, and end results analysis. BMC Urol. 22(42)2022.PubMed/NCBI View Article : Google Scholar | |
|
Würnschimmel C, Wenzel M, Ruvolo CC, Nocera L, Tian Z, Saad F, Briganti A, Shariat SF, Mirone V, Chun FK, et al: Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. Int J Urol. 28:862–869. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Huynh-Le MP, Karunamuni R, Fan CC, Thompson WK, Muir K, Lophatananon A, Tye K, Wolk A, Håkansson N, Mills IG, et al: Common genetic and clinical risk factors: Association with fatal prostate cancer in the Cohort of Swedish Men. Prostate Cancer Prostatic Dis. 24:845–851. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Abd Ellatif M, Gamal BE, Musaam AO, Malik A and Tarique M: An update on genetic predisposition for prostate cancer: Perspectives and prospects. Cell Mol Biol. 69:1–7. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Raghallaigh HN and Eeles R: Genetic predisposition to prostate cancer: An update. Fam Cancer. 21:101–114. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Benafif S, Raghallaigh HN, McHugh J and Eeles R: Genetics of prostate cancer and its utility in treatment and screening. Adv Genet. 108:147–199. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Korneenko TV and Pestov NB: Oncogenic BRCA1,2 mutations in the human lineage-A By-product of sexual selection? Biomedicines. 12(22)2024.PubMed/NCBI View Article : Google Scholar | |
|
Kalampokis N, Zabaftis C, Spinos T, Karavitakis M, Leotsakos I, Katafigiotis I, van der Poel H, Grivas N and Mitropoulos D: Review on the role of BRCA mutations in genomic screening and risk stratification of prostate cancer. Curr Oncol. 31:1162–1169. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Januskevicius T, Vaicekauskaite I, Sabaliauskaite R, Matulevicius A, Vezelis A, Ulys A, Jarmalaite S and Jankevicius F: Germline DNA damage response gene mutations in localized prostate cancer. Medicina (Kaunas). 60(73)2024.PubMed/NCBI View Article : Google Scholar | |
|
Akhoundova D, Francica P, Rottenberg S and Rubin MA: DNA damage response and mismatch repair gene defects in advanced and metastatic prostate cancer. Adv Anat Pathol. 31:61–69. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Freedland SJ, Samjoo IA, Rosta E, Lansing A, Worthington E, Niyazov A, Nazari J and Arondekar B: The impact of race on survival in metastatic prostate cancer: A systematic literature review. Prostate Cancer Prostatic Dis. 26:461–474. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, et al: Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate. 81:433–439. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Schiff J, Ledet EM, Ernst EM, Garvey CE, Cotogno P and Sartor O: J Clin Oncol 35: 6 suppl, 2017. https://ascopubs.org/doi/10.1200/JCO.2017.35.6_suppl.225. | |
|
Zhang W and Zhang K: Quantifying the contributions of environmental factors to prostate cancer and detecting risk-related diet metrics and racial disparities. Cancer Inform. 22(11769351231168006)2023.PubMed/NCBI View Article : Google Scholar | |
|
Roach M III, Coleman PW and Kittles R: Prostate cancer, race, and health disparity. Cancer J. 29:328–337. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Epstein M, Syed K, Danella J, Ginzburg S, Belkoff L, Tomaszewski J, Trabulsi E, Singer EA, Jacobs BL, Raman JD, et al: Model risk scores may underestimate rate of biochemical recurrence in African American men with localized prostate cancer: A cohort analysis of over 3,000 men. Prostate Cancer Prostatic Dis. 27:257–263. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Deuker M, Stolzenbach LF, Pecoraro A, Rosiello G, Luzzago S, Tian Z, Saad F, Chun FK and Karakiewicz PI: PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions. World J Urol. 39:787–796. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Hoeh B, Hohenhorst JL, Flammia R, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, et al: Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. Int Urol Nephrol. 54:81–87. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Stern N, Ly TL, Welk B, Chin J, Ballucci D, Haan M and Power N: Association of race and ethnicity with prostate cancer-specific mortality in Canada. JAMA Netw Open. 4(e2136364)2021.PubMed/NCBI View Article : Google Scholar | |
|
Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, West DW, Teh CZ and Stamey T: Family history and prostate-cancer risk in black, white, and Asian men in the United-States and Canada. Am J Epidemiol. 141:732–740. 1995.PubMed/NCBI View Article : Google Scholar | |
|
El Khoury CJ and Clouston SAP: Racial/Ethnic disparities in prostate cancer 5-year survival: The role of health-care access and disease severity. Cancers (Basel). 15(4284)2023.PubMed/NCBI View Article : Google Scholar | |
|
Yamoah K, Lee KM, Awasthi S, Alba PR, Perez C, Anglin-Foote TR, Robison B, Gao A, DuVall SL, Katsoulakis E, et al: Racial and ethnic disparities in prostate cancer outcomes in the veterans affairs health care system. JAMA Netw Open. 5(e2144027)2022.PubMed/NCBI View Article : Google Scholar | |
|
Stevens C, Hightower A, Buxbaum SG, Falzarano SM and Rhie SK: Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients. Front Oncol. 13(e2144027)2023.PubMed/NCBI View Article : Google Scholar | |
|
Stangl A, Wilner C, Li P, Maahs L, Hwang C and Pilling A: Molecular features and race-associated outcomes of mutant metastatic castration-resistant prostate cancer. Prostate. 83:524–533. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Kanayama M, Chen Y, Rabizadeh D, Vera L, Lu C, Nielsen SM, Russell EM, Esplin ED, Wang H, Isaacs WB, et al: Clinical and functional analyses of an African-ancestry gain-of-function HOXB13 variant implicated in aggressive prostate cancer. Eur Urol Oncol. 7:751–759. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Wei J, Beebe-Dimmer J, Shi Z, Sample C, Yan G, Rifkin AS, Sadeghpour A, Gielzak M, Choi S, Moon D, et al: Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry. Prostate. 83:454–461. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Thakker PU, Perry AG, Hemal AK, Bercu CH, Petrou SP, Pak RW, Broderick GA, Thiel DD, Dora CD, Lyon TD, et al: Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category ‘D’ recommendation against prostate-specific antigen screening: A retrospective cohort study. Transl Androl Urol. 13:1093–1103. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Ruvolo CC, Würnschimmel C, Nocera L, Wenzel M, Tian Z, Shariat SF, Saad F, Verze P, Imbimbo C, Briganti A, et al: Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. Int J Urol. 28:1247–1252. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Lim J, Malek R, Jr S, Toh CC, Sundram M, Woo SYY, Yusoff NAM, Teh GC, Chui BJT, Ng IS, et al: Prostate cancer in multi-ethnic Asian men: Real-world experience in the Malaysia prostate cancer (M-CaP) study. Cancer Med. 10:8020–8028. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Stopsack KH, Nandakumar S, Arora K, Nguyen B, Vasselman SE, Nweji B, McBride SM, Morris MJ, Rathkopf DE, Slovin S, et al: Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors. Clin Cancer Res. 28:318–326. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Sani MM, Kloping Y and Surahmad F: Benign prostatic hyperplasia genetic variants in Asians. Clin Chim Acta. 565(119986)2024.PubMed/NCBI View Article : Google Scholar | |
|
Graham NJ, Souter LH and Salami SS: A systematic review of family history, Race/Ethnicity, and genetic risk on prostate cancer detection and outcomes: Considerations in PSA-based screening. Urol Oncol. 15:S1078–S1143. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Chiong E, Murphy DG, Buchan N, Chen K, Chen SS, Chua MLK, Hamid AR, Kanesvaran R, Khochikar M, Letran J, et al: Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific advanced prostate cancer consensus conference 2023. Asia Pac J Clin Oncol. 20:481–490. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Liu VN, Van Blarigan EL, Zhang L, Graff RE, Loeb S, Langlais CS, Cowan JE, Carroll PR, Chan JM and Kenfield SA: Plant-based diets and disease progression in men with prostate cancer. JAMA Netw Open. 7(e249053)2024.PubMed/NCBI View Article : Google Scholar | |
|
Mitchell E, Comerford K, Knight M, McKinney K and Lawson Y: A review of dairy food intake for improving health among black adults in the US. J Natl Med Assoc. 116:253–273. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Kimura T and Egawa S: Epidemiology of prostate cancer in Asian countries. Int J Urol. 25:524–531. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ge S, Zha L, Sobue T, Kitamura T, Ishihara J, Iwasaki M, Inoue M, Yamaji T, Tsugane S and Sawada N: Dietary consumption of antioxidant vitamins in relation to prostate cancer risk in Japanese men: The Japan public health center-based prospective study. J Epidemiol. 34:144–153. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Krishnan S, Kanthaje S, Punchappady DR, Mujeeburahiman M and Ratnacaram CK: Circulating metabolite biomarkers: A game changer in the human prostate cancer diagnosis. J Cancer Res Clin Oncol. 149:951–967. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Ko YH and Kim BH: Should contemporary western guidelines based on studies conducted in the 2000s be adopted for the prostate-specific antigen screening policy for Asian men in the 2020s? World J Mens Health. 40:1–8. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Wang CM, Yuan L, Liu XH, Chen SQ, Wang HF, Dong QF, Zhang B, Huang MS, Zhang ZY, Xiao J and Tao T: Developing a diagnostic model for predicting prostate cancer: A retrospective study based on Chinese multicenter clinical data. Asian J Androl. 26:34–40. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Pandit AA, Halpern MT, Gressler LE, Kamel M, Payakachat N and Li C: Association of race/ethnicity and patient care experiences with receipt of definitive treatment among prostate cancer survivors: A SEER-CAHPS study. Cancer Causes Control. 35:647–659. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Alkhatib KY, Filipas DK, Briggs L, Frego N, Koelker M, Lipsitz SR, Pierorazio PM, Rebbeck T, Kilbridge K, Kibel AS, et al: Racial differences in knowledge, attitudes, and sources of information about germline cancer genetic testing in the USA: An analysis of the health information national trends survey system. Prev Med. 178(107779)2024.PubMed/NCBI View Article : Google Scholar | |
|
Sweis J, Ofori B and Murphy AB: Concerns regarding prostate cancer screening guidelines in minority populations. Prostate Cancer Prostatic Dis. 27:591–593. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Sasaki T, Matsumoto R, Higashi S, Kato M, Masui S, Yoshio Y, Nishikawa K and Inoue T: Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy. Int J Urol. 29:1339–1346. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Xu J, Resurreccion WK, Shi Z, Wei J, Wang CH, Zheng SL, Hulick PJ, Ross AE, Pavlovich CP, Helfand B, et al: Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer Prostatic Dis. 25:422–430. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Giri VN, Morgan TM, Morris DS, Berchuck JE, Hyatt C and Taplin ME: Genetic testing in prostate cancer management: Considerations informing primary care. CA Cancer J Clin. 72:360–371. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Cui H, Zhang W, Zhang L, Qu Y, Xu Z, Tan Z, Yan P, Tang M, Yang C, Wang , et al: Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses. PLoS Med. 21(e1004362)2024.PubMed/NCBI View Article : Google Scholar | |
|
Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA and Morgan TM: Genetic risk prediction for prostate cancer: Implications for early detection and prevention. Eur Urol. 83:241–248. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Takeuchi T, Hattori-Kato M, Okuno Y, Nomiya A, Fukuhara H, Zaitsu M and Azuma T: A genome-wide association study of prostate cancer susceptibility using occupational and environmental factors as confounding factors. Cureus. 16(e52926)2024.PubMed/NCBI View Article : Google Scholar | |
|
Farashi S, Kryza T, Clements J and Batra J: Post-GWAS in prostate cancer: From genetic association to biological contribution. Nat Rev Cancer. 19:46–59. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Teerlink CC, Leongamornlert D, Dadaev T, Thomas A, Farnham J, Stephenson RA, Riska S, McDonnell SK, Schaid DJ, Catalona WJ, et al: Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. Hum Genet. 135:923–938. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Benafif S and Eeles R: Genetic predisposition to prostate cancer. Br Med Bull. 120:75–89. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hall R, Bancroft E, Pashayan N, Kote-Jarai Z and Eeles RA: Genetics of prostate cancer: A review of latest evidence. J Med Genet. 61:915–926. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Bıyıkoğlu M, Tanrıverdi R, Bozlu M, Şenel S, Fidancı ŞB, Tamer L and Akbay E: Evaluation of homeobox protein B13 (HOXB13) gene G84E mutation in patients with prostate cancer. World J Urol. 42(476)2024.PubMed/NCBI View Article : Google Scholar | |
|
Heise M, Jarzemski P, Nowak D, Bąk A, Junkiert-Czarnecka A, Pilarska-Deltow M, Borysiak M, Pilarska B and Haus O: Clinical significance of gene mutations and polymorphic variants and their association with prostate cancer risk in Polish men. Cancer Control. 29(10732748211062342)2022.PubMed/NCBI View Article : Google Scholar | |
|
Nyberg T, Brook MN, Ficorella L, Lee A, Dennis J, Yang X, Wilcox N, Dadaev T, Govindasami K, Lush M, et al: CanRisk-Prostate: A comprehensive, externally validated risk model for the prediction of future prostate cancer. J Clin Oncol. 41:1092–1104. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Dairo O, DePaula Oliveira L, Schaffer E, Vidotto T, Mendes AA, Lu J, Huynh SV, Hicks J, Sowalsky AG, De Marzo AM, et al: Gene methylation is associated with fatty acid synthase expression and clinical-genomic features of prostate cancer. Cancer Res Commun. 4:152–163. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Panebianco M, Cereda V and D'Andrea MR: Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: A review of the recent phase III trials. Explor Target Antitumor Ther. 5:997–1010. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Zhao D, Wang A, Li Y, Cai X, Zhao J, Zhang T, Zhao Y, Dong Y, Zhou F, Li Y and Wang J: Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors. J Natl Cancer Cent. 4:280–287. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Castro E: PARP inhibitor addition to androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer should be limited to BRCA mutation carriers. Eur Urol Focus. 10:504–505. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Hassanin E, May P, Aldisi R, Spier I, Forstner AJ, Nöthen MM, Aretz S, Krawitz P, Bobbili DR and Maj C: Breast and prostate cancer risk: The interplay of polygenic risk, rare pathogenic germline variants, and family history. Genet Med. 24:576–585. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Oliynyk RT: Evaluating the potential of younger cases and older controls cohorts to improve discovery power in genome-wide association studies of late-onset diseases. J Pers Med. 9(38)2019.PubMed/NCBI View Article : Google Scholar | |
|
Graff RE, Möller S, Passarelli MN, Witte JS, Skytthe A, Christensen K, Tan Q, Adami HO, Czene K, Harris JR, et al: Familial risk and heritability of colorectal cancer in the nordic twin study of cancer. Clin Gastroenterol Hepatol. 15:1256–1264. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Ponti G, De Angelis C, Ponti R, Pongetti L, Losi L, Sticchi A, Tomasi A and Ozben T: Hereditary breast and ovarian cancer: From genes to molecular targeted therapies. Crit Rev Clin Lab Sci. 60:640–650. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Abdel-Razeq H, Sharaf B, Tamimi F, Hani HB, Alsmadi O, Khalil H, Abunasser M, Edaily S and Mansour A: Establishment of a clinical cancer genetics program for breast cancer in a resource-limited country; challenges and opportunities. Front Oncol. 14(1431985)2024.PubMed/NCBI View Article : Google Scholar | |
|
Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, Allen S, Garrett A, Torr B, Bacon A, et al: Second primary cancer risks after breast cancer in BRCA1 and BRCA2 pathogenic variant carriers. J Clin Oncol. 29(JCO2401146)2024.PubMed/NCBI View Article : Google Scholar | |
|
Fanale D, Corsini LR, Brando C, Randazzo U, Bono M, Pedone E, Perez A, Sciacchitano R, Cancelliere D, Piraino P, et al: BRCA-associated hereditary male cancers: Can gender affect the prevalence and spectrum of germline pathogenic variants? Front Oncol. 14(1414343)2024.PubMed/NCBI View Article : Google Scholar | |
|
John AO, Singh A, Yadav P, Joel A, Thumaty DB, Ninan KF, Georgy JT, Cherian AJ, Thomas S, Thomas A, et al: The BRCA mutation spectrum among breast and ovarian cancers in India: Highlighting the need to screen BRCA1 185delAG among South Indians. Eur J Hum Genet. 32:1319–1326. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Marino F, Totaro A, Gandi C, Bientinesi R, Moretto S, Gavi F, Pierconti F, Iacovelli R, Bassi P and Sacco E: Germline mutations in prostate cancer: A systematic review of the evidence for personalized medicine. Prostate Cancer Prostatic Dis. 26:655–664. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Lukashchuk N, Barnicle A, Adelman CA, Armenia J, Kang J, Barrett JC and Harrington EA: Impact of DNA damage repair alterations on prostate cancer progression and metastasis. Front Oncol. 13(1162644)2023.PubMed/NCBI View Article : Google Scholar | |
|
Bugoye FC, Torrorey-Sawe R, Biegon R, Dharsee N, Mafumiko FMS, Patel K and Mining SK: Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer. Front Genet. 14(1231536)2023.PubMed/NCBI View Article : Google Scholar | |
|
Zhang D, Xu X, Wei Y, Chen X, Li G, Lu Z, Zhang X, Ren X, Wang S and Qin C: Prognostic role of DNA damage response genes mutations and their association with the sensitivity of olaparib in prostate cancer patients. Cancer Control. 29(10732748221129451)2022.PubMed/NCBI View Article : Google Scholar | |
|
Reiter K and Hassler MR: Genetic testing and management of prostate cancer patients with pathogenic germline variants. Memo-Magazine of European Medical Oncology. 17:51–56. 2024. | |
|
Steinkellner L, Luger F and Loidl W: Importance of genetic testing in prostate cancer. Urologie. 61:1392–1396. 2022.PubMed/NCBI View Article : Google Scholar : (In German). | |
|
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, Gore JL, Paradysz A, Tilki D, Merseburger AS, et al: Prostate cancer risk, screening and management in patients with germline mutations. Nat Rev Urol. 20:205–216. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Inoue T, Sekito S, Kageyama T, Sugino Y and Sasaki T: Roles of the PARP inhibitor in BRCA1 and BRCA2 pathogenic mutated metastatic prostate cancer: Direct functions and modification of the tumor microenvironment. Cancers (Basel). 15(2662)2023.PubMed/NCBI View Article : Google Scholar | |
|
Chen JY, Wang PY, Liu MZ, Lyu F, Ma MW, Ren XY and Gao XS: Biomarkers for prostate cancer: From diagnosis to treatment. Diagnostics (Basel). 13(3350)2023.PubMed/NCBI View Article : Google Scholar | |
|
Petrucelli N, Daly MB and Pal T: BRCA1- and BRCA2-associated hereditary breast and ovarian cancer, In GeneReviews((R)), M.P. Adam et al., Editors. 1993: Seattle (WA). | |
|
Ragupathi A, Singh M, Perez AM and Zhang D: Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights. Front Cell Dev Biol. 11(1133472)2023.PubMed/NCBI View Article : Google Scholar | |
|
Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, Chittenden A, Kane S, Stokes S, Hughes ME, et al: Identification and management of pathogenic variants in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program. Clin Cancer Res. 28:2349–2360. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K, Shiroki R and Saya H: Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer. Cancer Med. 12:8154–8165. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Foley GR, Marthick JR, Ostrander EA, Stanford JL, Dickinson JL and FitzGerald LM: Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing. Eur J Cancer. 180:155–157. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Nyberg T, Tischkowitz M and Antoniou AC: BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: Systematic review and meta-analysis. Br J Cancer. 126:1067–1081. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Xie C, Luo J, He Y, Jiang L, Zhong L and Shi Y: BRCA2 gene mutation in cancer. Medicine (Baltimore). 101(e31705)2022.PubMed/NCBI View Article : Google Scholar | |
|
Hongo H, Kosaka T, Hayashi H, Nakamura K, Nishihara H, Mikami S, Beltran H and Oya M: Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. Asian J Androl. 24:116–118. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Thorne H, Devereux L, Li J, Alsop K, Christie L, van Geelen CT, Burdett N, Pishas KI, Woodford N, Leditschke J, et al: BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: Results from a rapid autopsy programme. Histopathology. 83:91–103. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Paulo P, Cardoso M, Brandão A, Pinto P, Falconi A, Pinheiro M, Cerveira N, Silva R, Santos C, Pinto C, et al: Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients. Genes Chromosomes Cancer. 62:710–720. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Kwong A, Ho CYS, Shin VY, Ng ATL, Chan TL and Ma ESK: Molecular characteristics of Asian male-related cancers. Breast Cancer Res Treat. 198:391–400. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Fettke H, Dai C, Kwan EM, Zheng T, Du P, Ng N, Bukczynska P, Docanto M, Kostos L, Foroughi S, et al: BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype. EbioMedicine. 95(104738)2023.PubMed/NCBI View Article : Google Scholar | |
|
Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, et al: Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using polygenic risk scores. J Natl Cancer Inst. 114:109–122. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Marchetti C, Ataseven B, Cassani C, Sassu CM, Congedo L, D'Indinosante M, Cappuccio S, Rhiem K, Hahnen E, Cordisco EL, et al: Ovarian cancer onset across different mutation types: A view to a more tailored approach for BRCA mutated patients. Int J Gynecol Cancer. 33:257–262. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Osman K, Ahmet K, Hilmi T, İlker NO, Ercan Ö, Devrim Ç, Murat S, Emre Ç, İlhan H, Mustafa G, et al: BRCA 1/BRCA 2 pathogenic/likely pathogenic variant patients with breast, ovarian, and other cancers. Balkan J Med Genet. 25:5–14. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Mitsueda R, Toda H, Shinden Y, Fukuda K, Yasudome R, Kato M, Kikkawa N, Ohtsuka T, Nakajo A and Seki N: Oncogenic targets regulated by tumor-suppressive miR-30c-1-3p and miR-30c-2-3p: TRIP13 facilitates cancer cell aggressiveness in breast cancer. Cancers (Basel). 15(4189)2023.PubMed/NCBI View Article : Google Scholar | |
|
Loboda AP, Adonin LS, Zvereva SD, Guschin DY, Korneenko TV, Telegina AV, Kondratieva OK, Frolova SE, Pestov NB and Barlev NA: BRCA mutations-the achilles heel of breast, ovarian and other epithelial cancers. Int J Mol Sci. 24(4982)2023.PubMed/NCBI View Article : Google Scholar | |
|
Lavoro A, Scalisi A, Candido S, Zanghì GN, Rizzo R, Gattuso G, Caruso G, Libra M and Falzone L: Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families? Int J Oncol. 60(58)2022.PubMed/NCBI View Article : Google Scholar | |
|
Werner H: BRCA1: An endocrine and metabolic regulator. Front Endocrinol (Lausanne). 13(844575)2022.PubMed/NCBI View Article : Google Scholar | |
|
Russi M, Marson D, Fermeglia A, Aulic S, Fermeglia M, Laurini E and Pricl S: The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer. Pharmacol Ther. 232(108009)2022.PubMed/NCBI View Article : Google Scholar | |
|
Lee CL, Holter S, Borgida A, Dodd A, Ramotar S, Grant R, Wasson K, Elimova E, Jang RW, Moore M, et al: Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature. World J Gastroenterol. 28:6421–6432. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Boussios S, Rassy E, Moschetta M, Ghose A, Adeleke S, Sanchez E, Sheriff M, Chargari C and Pavlidis N: BRCA mutations in ovarian and prostate cancer: Bench to bedside. Cancers (Basel). 14(3888)2022.PubMed/NCBI View Article : Google Scholar | |
|
Werner H and Laron Z: Role of the GH-IGF1 system in progression of cancer. Mol Cell Endocrinol. 518(111003)2020.PubMed/NCBI View Article : Google Scholar | |
|
Sharon SM, Pozniak Y, Geiger T and Werner H: TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: Involvement of transcription factor Sp1. Oncotarget. 7:51375–51392. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Alanee SR, Glogowski EA, Schrader KA, Eastham JA and Offit K: Clinical features and management of BRCA1 and BRCA2-associated prostate cancer. Front Biosci (Elite Ed). 6:15–30. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E and Greco M: Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Sci. 99:553–563. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Rein HL and Bernstein KA: Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond. DNA Repair (Amst). 130(103563)2023.PubMed/NCBI View Article : Google Scholar | |
|
Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, et al: Prostate cancer in germline mutation carriers is associated with poorer prognosis. Br J Cancer. 103:918–924. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, et al: Two percent of men with early-onset prostate cancer harbor germline mutations in the gene. Am J Hum Genet. 72:1–12. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K and Robson ME: Germline mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int. 109:713–719. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Halldén C, et al: Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res. 16:2819–2832. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J, Clouston D, Mitchell G, Fox S and Hopper JL: Kathleen Cunningham Consortium for Research in Familial Breast Cancer Consortium. Bolton D: Decreased prostate cancer-specific survival of men with mutations from multiple breast cancer families. Cancer Prev Res (Phila). 4:1002–1010. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE and Tulinius H: Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst. 99:929–935. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, et al: Rapid progression of prostate cancer in men with a mutation. Br J Cancer. 99:371–374. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Castro E, Jugurnauth-Little S, Karlsson Q, Al-Shahrour F, Piñeiro-Yañez E, Van de Poll F, Leongamornlert D, Dadaev T, Govindasami K, Guy M, et al: High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. Ann Oncol. 26:2293–2300. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Castro E, Salles DC, Lozano R, Thorne H, Aragon I, Campos FL, Rubio J, Pecharroman AG, Prieto D, Lozano IG, et al: Association between BRCA2 status and histologic variants (intraductal (IDC) and cribriform (CRIB) histology) in prostate cancer (PC). J Clin Oncol. 38:74–83. 2020. | |
|
Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, et al: Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 31:1748–1757. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Shee K, Cowan JE, Balakrishnan A, Escobar D, Chang K, Washington SL III, Nguyen HG, Shinohara K, Cooperberg MR and Carroll PR: Limited relevance of the very low risk prostate cancer classification in the modern era: Results from a large institutional active surveillance cohort. Eur Urol. 84:9–12. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Xie M, Gao XS, Ma MW, Gu XB, Li HZ, Lyu F, Bai Y, Chen JY, Ren XY and Liu MZ: Population-based comparison of different risk stratification systems among prostate cancer patients. Front Oncol. 11(646073)2021.PubMed/NCBI View Article : Google Scholar | |
|
Ellis SD, Blackard B, Carpenter WR, Mishel M, Chen RC, Godley PA, Mohler JL and Bensen JT: Receipt of national comprehensive cancer network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer. 119:2282–2290. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Ueki A, Yoshida R, Kosaka T and Matsubayashi H: Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for variant carriers in Japan. J Hum Genet. 68:517–526. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Militaru FC, Militaru V, Crisan N, Bocsan IC, Udrea AA, Catana A, Kutasi E and Militaru MS: Molecular basis and therapeutic targets in prostate cancer: A comprehensive review. Biomol Biomed. 23:760–771. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Margel D, Benjaminov O, Ozalvo R, Grievink LS, Kedar I, Yerushalmi R, Ben-Aharon I, Neiman V, Yossepowitch O, Kedar D, et al: Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study. BMC Cancer. 14(528)2014.PubMed/NCBI View Article : Google Scholar | |
|
Wan A, Zhang G, Ma D, Zhang Y and Qi X: An overview of the research progress of BRCA gene mutations in breast cancer. Biochim Biophys Acta Rev Cancer. 1878(188907)2023.PubMed/NCBI View Article : Google Scholar | |
|
Slootbeek PHJ, Overbeek JK, Ligtenberg MJL, van Erp NP and Mehra N: PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer. Cancer Lett. 577(216367)2023.PubMed/NCBI View Article : Google Scholar | |
|
Xu J, Ma C, Hirschey R, Liu J, Neidre DB, Nielsen ME, Keyserling TC, Tan X and Song L: Associations of role, area deprivation index, and race with health behaviors and body mass index among localized prostate cancer patients and their partners. J Cancer Surviv. 18(10.1007/s11764-024-01625-z)2024.PubMed/NCBI View Article : Google Scholar | |
|
Trendowski MR, Ruterbusch JJ, Baird TE, Wenzlaff AS, Pandolfi SS, Hastert TA, Schwartz AG and Beebe-Dimmer JL: Correlates of health-related quality of life in African Americans diagnosed with cancer: A review of survivorship studies and the Detroit research on cancer survivors cohort. Cancer Metastasis Rev. 43:1373–1384. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Delgado D, Gillard M, Tong L, Demanelis K, Oliva M, Gleason KJ, Chernoff M, Chen L, Paner GP, Griend DV and Pierce BL: The impact of inherited genetic variation on DNA methylation in prostate cancer and benign tissues of African American and European American Men. Cancer Epidemiol Biomarkers Prev. 33:557–566. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Tipre M, Hardy C, Bowman T, Glover M, Gullet P, Baity D, Levy K and Baskin ML: Concept mapping with black men: Barriers to prostate cancer screening and solutions. J Cancer Educ. 38:1808–1815. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Wang EY, Borno HT, Washington Iii SL, Friedlander T, Zhang S, Trejo E, Van Blarigan EL, Chan JM, Shariff-Marco S, Beatty AL and Kenfield S: Engaging men of diverse racial and ethnic groups with advanced prostate cancer in the design of an mHealth diet and exercise intervention: Focus group study. JMIR Cancer. 9(e45432)2023.PubMed/NCBI View Article : Google Scholar | |
|
Lei F and Lee E: Cancer screening rates among Asian Americans: A cross-sectional secondary data analysis study. Cancer Control. 30(10732748231202462)2023.PubMed/NCBI View Article : Google Scholar | |
|
Wadhwa A, Han K, Ramirez-Velandia F, Alwakaa O, Riordan C, McNeil E, Granstein JH, Taussky P, Enriquez-Marulanda A, Ogilvy CS, et al: Neighborhood deprivation, race and ethnicity, and prostate cancer outcomes across California health care systems. JAMA Netw Open. 7(e242852)2024.PubMed/NCBI View Article : Google Scholar | |
|
Frego N, Beatrici E, Labban M, Stone BV, Filipas DK, Koelker M, Lughezzani G, Buffi NM, Osman NY, Lipsitz SR, et al: Racial disparities in prostate cancer screening: The role of shared decision making. Am J Prev Med. 66:27–36. 2024.PubMed/NCBI View Article : Google Scholar |
